Prof. Dr. Adil Mardinoğlu is appointed as Chair of TÜSEB


Prof. Dr. Adil Mardinoğlu was appointed as Chair of TÜSEB (Health Institutes of Turkey) by Health Minister Dr. Fahrettin Koca, and stepped in following the handover ceremony organized at the Istanbul campus in the presence of Deputy Minister of Health Prof. Dr. Emine Alp Meşe.

Prof. Dr. Adil Mardinoğlu is an electrical and electronic engineer working in the field of drug technologies abroad. Prof. Dr. Hasan Türkez, one of the best nanotechnology experts, was also appointed as the Secretary-General of TÜSEB.

Established in 2015 in order to conduct researches in the field of health sciences and technologies, and support the scientific studies, TÜSEB is one of the most important milestones for “localization” vision of the Ministry. In line with this target, Prof. Adiloğlu, who had been working for years in the area of molecular biology and pharmaceutical development abroad, was appointed as the chair of TÜSEB.

After graduating from the Faculty of Electrical and Electronic Engineering, Istanbul University, Prof. Mardinoğlu obtained his PhD from Waterford Institute of Technology, Ireland in the field of “magnetic drug targeting”. He worked on drug technologies at the leading universities of Ireland, Sweden and England and recently led a team researching cell working principles and disease mechanisms at King’s College of London and KTH-Royal Institute of Technology. He was working on innovative drugs and early diagnosis systems for chronic diseases (diabetics and fatty liver syndrome), cancer and neurodegenerative diseases.

Prof. Dr. Hasan Türkez, the newly appointed Secretary-General of TÜSEB, graduated from Biology Department, Atatürk University. He completed his first PhD at Institute of Sciences of the same university in the field of genetics, and his second PhD at Chieti-Pescara University, Italy in the field of drug technologies. Named as one of the best nanotechnology experts of the world by Webometrics in 2018, Prof. Türkez also served as the toxicology and epidemiology expert for two different committees at WHO. His main areas of research are nanotechnology-based drug carrier systems, cancer biology, boron biology, genetic toxicology, neurodegenerative diseases and molecular pharmacology. He also served as the project manager for the projects supported by National Boron Research Institute for developing medical and pharmacological use potential of boron and also by TÜBİTAK for developing new molecules for the treatment of neurodegenerative diseases.       


Updated: 10/06/2019